Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Motixafortide→

Motixafortide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
664334-36-5
Molecular formula
C97H144FN33O19S2
Molecular weight
2159.6 g/mol
Drug class
C-X-C chemokine receptor 4 (CXCR4) antagonisthaematopoietic stem-cell mobiliser
Mechanism of action
Blocks CXCR4 binding to its ligand CXCL12/SDF-1α, disrupting retention and homing of haematopoietic stem cells in the bone marrow and mobilising CD34-positive stem cells into peripheral blood.
Indications / reported uses
  • In combination with filgrastim (G-CSF) to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma; not indicated for stem-cell mobilisation in leukaemia

Sources: NLM DailyMed — APHEXDA (motixafortide), updated 28 October 2025 · Manufacturer prescribing information — APHEXDA · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Motixafortide Environmental Risk Assessment (ERA) (the Motixafortide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.